CN109172712A - The purposes of palm berry extract - Google Patents
The purposes of palm berry extract Download PDFInfo
- Publication number
- CN109172712A CN109172712A CN201811170397.3A CN201811170397A CN109172712A CN 109172712 A CN109172712 A CN 109172712A CN 201811170397 A CN201811170397 A CN 201811170397A CN 109172712 A CN109172712 A CN 109172712A
- Authority
- CN
- China
- Prior art keywords
- extract
- ratio
- extraction
- palm
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 235000021028 berry Nutrition 0.000 title claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 37
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 20
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 20
- 229940116369 pancreatic lipase Drugs 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 17
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 17
- 235000013402 health food Nutrition 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 51
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 49
- 238000000605 extraction Methods 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012071 phase Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005238 degreasing Methods 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 6
- 239000008103 glucose Substances 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000031700 light absorption Effects 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- YNGNVZFHHJEZKD-UHFFFAOYSA-N (4-nitrophenyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 YNGNVZFHHJEZKD-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000731475 Trachycarpus Species 0.000 description 1
- 241001593750 Turcica Species 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical group 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the purposes of palm berry extract, i.e. its application in the drug or health food for inhibiting pancreatic lipase and alpha-glucosidase, belong to food or pharmaceutical technology field；The present invention is using palm fruit as raw material, utilize organic reagent, or water and organic reagent mixed liquor extract, obtain palm fruit difference extract, the present invention confirms that all extracts can effectively inhibit the activity of pancreatic lipase and alpha-glucosidase through external pancreatic lipase and alpha-glucosidase activity experiment, reduces the absorption of fat and glucose, therefore, the present invention can be used for preparing the health food and drug of the related diseases such as lower blood-fat and reduce weight, hypoglycemic.
Description
Technical field
The present invention relates to the food and medicine new applications of palm berry extract, belong to food or pharmaceutical technology field.
Background technique
With the continuous improvement of people 's material life, unsound high glucose and high fat diet and bad life habits induction are a variety of
The generation of chronic disease.Lipid it is excessive take in and movement there is a serious shortage of cause fat deposition in corporal parts, gradually
Evolve into obesity.Obesity is increased at present with surprising rate, and jeopardizing the whole world, especially there is high fat diet to be accustomed to state
The health of family's population, it has also become a global healthy topic.It is fat related with many chronic diseases, such as diabetes, fat
Liver and cardiovascular disease etc. show that fat death toll is significantly larger than the light people of weight, and sends out according to World Health Organization's data
Up to the Genus Homo in country there are about 65% in obese people.In addition, obese people induces glycosuria when fat often with blood glucose problem
After being ill, high-carbonhydrate diet can further deteriorate the development of diabetes, aggravate the complication of diabetes.Fat and carbon aquation in food
It closes object to need to be absorbed by the body after the hydrolysis of digestive ferment corresponding in gastrointestinal tract, wherein fat is mainly by pancreas fat
Digestion is hydrolyzed in enzyme, and carbohydrate is mainly hydrolyzed by alpha-glucosidase.Therefore, by inhibiting pancreatic lipase and α-sugar
The activity of glycosides enzyme delays the absorption of post prandial fat and glucose, strong so as to which fat, hyperlipidemia and hyperglycemia etc. is effectively relieved
Kang Wenti.So finding and developing new drug and health food actively to control the unhealthy shadow of high glucose and high fat diet bring
Sound is most important.
Currently, market is mainly orlistat for the inhibitor of pancreatic lipase, and clinical diabetes have been approved for it
The alpha-glucosidase inhibitor for the treatment of mainly has acarbose, voglibose and Miglitol.Although these inhibitor have good
Good function and effect, but usually along with certain side effect.In addition, it is often more important that these inhibitor are typically only capable to single
Ground is directed to pancreatic lipase or alpha-glucosidase, can not simultaneously effective inhibit the activity of pancreatic lipase and alpha-glucosidase, thus
Cause patient that need to take two different enzyme inhibitors simultaneously, do not increase drug cost singly, causes medication trouble, in some instances it may even be possible to
Drug interaction can be caused to aggravate side effect.Novel compound digestive enzyme inhibitor is all actively being found to same in the whole world at present
When inhibit pancreatic lipase and alpha-glucosidase activity, to cope with obesity increasingly serious brought by high glucose and high fat diet, height
The related diseases problem such as blood lipid and diabetes.Therefore, novel pancreatic lipase and seeking for the compound inhibitor of alpha-glucosidase have
Extremely important meaning.
Palm fruit is a kind of large-scale tropical oil crops, belongs to Angiospermae Monocotyledonae Trachycarpus, fruit is in orange
Red, in have stone, there are Malaysia, Indonesia etc. in the main place of production, and also there are a large amount of distributions in Hainan Province of China and Yunnan Province.
The main application of palm fruit is used as extracting oil, and oil yield is high, and the edible oil in the whole world about 1/4 is supplied by it.In addition, palm fruit
The nutritional ingredients such as carrotene, VitAVitE and polyphenols are also enriched in, long-term consumption is effective against human body oxygen
Change aging, reduces the generation of cardiovascular disease.But at present about the extract of palm fruit difference polyphenol for pancreatic lipase and
There has been no document reports for the correlative study of alpha-glucosidase inhibitor.
Summary of the invention
The object of the present invention is to provide the new applications of palm berry extract, for being used as digestive ferment (pancreatic lipase and α-Portugal
Polyglycoside enzyme) inhibitor, and it is used to prepare lower blood-fat and reduce weight, hypoglycemic drug or health food.
Preparing for palm berry extract of the present invention is as follows:
It (is quality that methanol-acetone mixed liquor, which is added, in solid-liquid ratio g:mL for the ratio of 1:4-6, in the palm fruit powder after degreasing
The ratio of concentration 70-80% methanol solution and mass concentration 70-80% acetone soln 1:1-1:3 by volume are mixed to prepare), it mixes
Ultrasonic extraction 20-40min afterwards, ultrasonic power 200-300W, filtering, filter residue is repeated and is mentioned 2-3 times, collects merging filtrate
Revolving removal organic reagent, collects the extraction that water phase is used to dissociate and be esterified state polyphenol；The extraction of free state polyphenol is first to use
Water phase pH is adjusted to 2-3 by 6mol/L hydrochloric acid, then with ether-acetic acid ethyl ester mixed liquor (volume ratio 1:1-1:3) extraction water
Phase, until extract liquor is colourless, combining extraction liquid simultaneously rotates freeze-drying, obtains free state polyphenol extract；It is esterified state polyphenol
Extraction is that at room temperature, the ratio for being 1:1-1:2 in water phase and sodium hydroxide solution volume ratio is added 4-6 in water phase
Mol/LNaOH solution hydrolyzes 4-8 h, is then 2-3 with 6mol/L salt acid for adjusting pH, then uses ether-acetic acid ethyl ester mixed liquor
(volume ratio 1:1-1:3) extraction, until extract liquor is colourless, combining extraction liquid revolving freeze-drying obtains esterification state polyphenol
Extract.
It is the ratio for being 1:1-3 in filter residue and sodium hydroxide solution volume ratio that reference state polyphenol, which extracts, after ultrasound filtration
Filter residue in be added 4-6 mol/LNaOH solution hydrolyze 4-8 h, be then 2-3 with 6mol/L salt acid for adjusting pH, then use second
Ether-ethyl acetate mixtures (volume ratio 1:1-1:3) extraction, until extract liquor is colourless, combining extraction liquid revolving is frozen
It is dry, obtain reference state polyphenol extract.
This invention address that the research of the chemical component of palm berry extract, inhibition digestive enzyme activity etc., through testing
Confirm that palm fruit is rich in polyphenol, polyphenol mainly exists with reference state；And its free, esterification and reference state polyphenol extract are equal
With the exact activity for inhibiting digestive ferment, the activity of pancreatic lipase and alpha-glucosidase can be inhibited significantly simultaneously.It therefore can
To be used to prepare and develop as lower blood-fat and reduce weight, hypoglycemic new drug or health food.Palm fruit polyphenol extract is used to prepare multiple
The drug or health food of mould assembly digestive enzyme inhibitor have these following advantages: palm fruit polyphenol extract can be from palm fruit
It is extracted in pomace after oil expression, not only can effectively solve the problem of environmental pollution of palm fruit pomace, palm fibre can also be effectively improved
The added value of palmitic acid fruit pomace increases its economic value, and palm fruit pomace abundant raw material, can be effectively reduced extract system
Standby cost；In addition, palm fruit itself is the raw material for oil expression, it is a kind of edible raw material, therefore, after being extracted with its pomace
Obtained polyphenol extract is highly-safe.The extraction of its different conditions polyphenol extract and preparation process flow be simple but market
Prospect is considerable, contains vast market prospect.
Compared with prior art, the present invention has the advantage that
1, the present invention is that palm fruit has excavated new health food or medical application, has opened up a new research field；
2, the present invention is found through experiments that palm fruit different conditions polyphenol extract can be effectively under the conditions of low concentration
Inhibit pancreatic lipase and alpha-glucosidase activity simultaneously；Other complication of the diseases such as hyperlipidemia, obesity and diabetes can be mitigated；
And palm fruit may be used for the fruit of food material, it is highly-safe.
Detailed description of the invention
Fig. 1 is the content of phenolic substances in palm fruit difference extract；
Fig. 2 is inhibitory activity of the palm fruit difference extract to pancreatic lipase；
Fig. 3 is inhibitory activity of the palm fruit difference extract to alpha-glucosidase.
Specific embodiment
Below with reference to specific implementation example, the invention will be further described, and the example of these experiments is merely to illustrate this hair
It is bright, it is not used in and limits application range of the invention.After having read record of the invention, the scientific and technical personnel of this field are to its etc.
Various changes, modification and the modification of effect, belong to the scope of the claims in the present invention.
Embodiment 1: the preparation of palm fruit different conditions polyphenol extract
Palm fruit powder 30g(petroleum ether degreasing according to a conventional method after weighing degreasing), methanol-is added by solid-liquid ratio g/mL1:5
Acetone mixture (be 70% methanol solution of mass concentration and 70% acetone soln of mass concentration by volume 1:1 ratio mixing system
), ultrasonic extraction, ultrasonic power 200W, the time is 30 minutes, then filters, filter residue is repeated and is mentioned 2 times, collect and close
And filtrate revolving removal organic reagent, it collects water phase and is respectively used to extraction that is free and being esterified state polyphenol.
The extraction of free state polyphenol: being first adjusted to 2 for water phase pH with 6mol/L hydrochloric acid, then mixed with ether-acetic acid ethyl ester
Liquid (1:1 v/v) extraction is closed, until extract liquor is colourless, combining extraction liquid simultaneously rotates freeze-drying, obtains free state polyphenol and mentions
Object is taken, and is stored in -20 DEG C.
Be esterified state polyphenol to extract: the ratio for being 1:1 in water phase and sodium hydroxide solution volume ratio is added in water phase
4mol/LNaOH solution hydrolyzes 4h, is then 2 with 6mol/L salt acid for adjusting pH, then uses ether-acetic acid ethyl ester mixed liquor (body
Product is than being 1:1) extraction, until extract liquor is colourless, combining extraction liquid revolving freeze-drying obtains esterification state polyphenol extract.
Reference state polyphenol extracts: the ratio for being 1:1 in filter residue and sodium hydroxide solution volume ratio, the filter after ultrasound filtration
4mol/LNaOH solution is added in slag and hydrolyzes 4h, is then 2 with 6mol/L salt acid for adjusting pH, it is then mixed with ether-acetic acid ethyl ester
Liquid (volume ratio 1:1) extraction is closed, until extract liquor is colourless, combining extraction liquid revolving freeze-drying obtains reference state
Polyphenol extract.
Embodiment 2: the identification of extract components
Material composition analysis is using HPLC-ESI-HRMS/MS identification in extract in embodiment 1, and specific as follows: splitter is
1.8 × 100 mm, 2 μm of C18 column, the formic acid water that water phase A is 2%, the Acidifying acetonitrile that organic phase B is 2%, separation elution ladder
Degree: 0-2 min, 5% B；2-10 min, 5-50% B；10-14 min, 50% B；14-15 min, 50-5% B；15-20 min,
5% B；Sample volume 3 μ L, 0.2 mL/min of flow velocity.Mass spectrometric data is acquired by Q-ExactiveOrbitrap mass spectrograph, relevant parameter
Are as follows: 3.3 kV of spray voltage, 350 DEG C of heter temperature, sheath gas 32L/min, assists gas by 320 DEG C of ion transfer tube temperature
Body flow velocity 8L/min, purge gas flow velocity 4L/min, 50-1000m/z of full scan range.By by mass spectrometric data and related data
Library and mark product compare, and identify more than ten substances altogether, wherein most is phenolic compound, and the results are shown in Table 1；
The chemical combination that three kinds of 1 palm fruit of table different extracts identify
。
Embodiment 3: the measurement of palm fruit difference extract total phenol content
Be measured using Forint phenol method, concrete operations are as follows: each extract is dissolved with methanol, is diluted to 1.0 mg/mL；It extracts
Object solution, forint phenol reagent respectively take 1mL to mix；1.5mL Na is added after standing 1 minute2CO3；10mL is settled to distilled water.70
DEG C water-bath 10 minutes, after being cooled to room temperature, light absorption value is measured at 765nm, the content of total phenol passes through the calculating of galla turcica acidity scale song
It obtains；As a result as shown in Figure 1, the total phenol content of each extract is respectively (mg gallic acid/g palm fruit): free state polyphenol
81.20 ± 6.07 mg/g are esterified 163.06 ± 3.06 mg/g of state polyphenol, 220.49 ± 14.43 mg/g of reference state polyphenol, from
As a result as can be seen that the phenolic substances in palm fruit mainly exists in the form of reference state polyphenol.
Embodiment 4: inhibition of the palm fruit difference extract to pancreatic lipase activity
Porcine pancreatic lipase is made into 15mg/mL with distilled water, and 10000rpm is centrifuged after five minutes, takes supernatant；In the sodium acetate of 5mM
The p-nitrophenyl laurate that 1% Qula X-100 and 1% is added in buffer solution is made into reaction substrate；Each extract of palm fruit
It is dissolved with DMSO, is diluted to debita spissitudo with Tris buffer solution (see Fig. 2)；Sample sets 100 μ L extract solutions of addition, 400
The sample solvent of 100 μ L is then added in μ L Tris buffer solution, 350 μ L substrate reactions liquids and 150 μ L enzyme solutions, blank control group；Respectively
Group is incubated for 2 hours after mixing in 37 DEG C, and incubation terminates, and 10000rpm centrifugation takes supernatant after five minutes, is measured at 400nm each
Group light absorption value.Pancreatic lipase inhibiting rate (%)=(ODcontrol-ODsample)/ODcontrol× 100, wherein ODsampleFor sample sets
Light absorption value, ODcontrolFor the light absorption value of blank control group.As a result as shown in Fig. 2, palm fruit difference polyphenol extract is to pancreas fat
Enzymatic activity has good inhibiting effect, and dosage effect is presented, the inhibitory activity IC of the polyphenol of three kinds of states to pancreatic lipase50
Value (μ g/mL) is respectively as follows: 141.51 ± 0.93 μ g/mL of free state polyphenol, is esterified 117.06 ± 1.90 μ g/mL of state polyphenol, in conjunction with
74.77 ± 1.02 μ g/mL of state polyphenol, from IC50Value can be seen that in three kinds of extracts, reference state polyphenol extract inhibitory effect
It is best.
Embodiment 5: the measurement that palm fruit difference polyphenol extract inhibits alpha-glucosidase activity
α-p-nitrophenyl glucoside is made into 2.5mmoL/L reaction substrate with the PBS buffer solution of pH=6.8, alpha-glucosidase is matched
At the enzyme solution of 1Unit/mL, palm fruit difference polyphenol extract methanol dilution is added 50 at various concentration (see figure 3), sample sets
The pure water of 50 μ L is then added in μ L extract solution and 100 μ L enzyme solutions, 25 DEG C of 10 min of incubation, blank control group；Incubation terminates
After 50 μ L substrate reactions liquids be added be incubated for 5min again；After reaction, each group light absorption value is measured at 405nm.Alpha-glucosaccharase
Enzyme inhibition rate (%)=(ODcontrol-ODsample)/ODcontrol× 100, wherein ODsampleFor the light absorption value of sample sets, ODcontrolFor
The light absorption value of blank control group.As a result as shown in figure 3, palm fruit difference polyphenol extract all shows alpha-glucosidase to inhibit to live
Property, IC50Value is respectively as follows: 128.64 ± 0.97 μ g/mL of free state polyphenol, is esterified 90.72 ± 1.45 μ g/mL of state polyphenol and reference state
74.25 ± 0.98 μ g/mL of polyphenol, it is therefore seen that, the inhibitory effect of reference state polyphenol is better than other two kinds of polyphenol.
In conclusion can determine that the different extracts of palm fruit can effectively inhibit pancreatic lipase and alpha-glucosidase
Activity, may thereby determine that palm berry extract can be used for preparing lower blood-fat and reduce weight, hypoglycemic drug or health food.
Claims (5)
1. application of the palm berry extract in the drug that preparation inhibits pancreatic lipase and alpha-glucosidase.
2. application of the palm berry extract in the health food that preparation inhibits pancreatic lipase and alpha-glucosidase.
3. application according to claim 1 or 2, it is characterised in that: it is 1:4- that palm berry extract, which is by solid-liquid ratio g:mL,
Methanol-acetone mixed liquor, ultrasonic extraction 20-40min, ultrasonic wave after mixing are added in the palm fruit powder after degreasing for 6 ratio
Power is 200-300W, and filter residue is repeated and mentioned 2-3 times by filtering, collects merging filtrate revolving removal organic reagent, collects water phase
For dissociating and being esterified the extraction of state polyphenol；The extraction of free state polyphenol is that water phase pH is first adjusted to 2-3 with 6mol/L hydrochloric acid,
Then ether-acetic acid ethyl ester mixed liquor aqueous phase extracted is used, until extract liquor is colourless, combining extraction liquid simultaneously rotates freeze-drying,
Obtain free state polyphenol extract；Being esterified the extraction of state polyphenol to be is 1 by water phase and sodium hydroxide solution volume ratio at room temperature:
4-6 mol/L NaOH solution is added in the ratio of 1-1:2 in water phase, hydrolyzes 4-8 h, is then with 6mol/L salt acid for adjusting pH
Then 2-3 is extracted with ether-acetic acid ethyl ester mixed liquor, until extract liquor is colourless, combining extraction liquid revolving freeze-drying is obtained
To esterification state polyphenol extract；The ratio for being 1:1-3 in filter residue and sodium hydroxide solution volume ratio, the filter residue after ultrasound filtration
Middle addition 4-6 mol/LNaOH solution hydrolyzes 4-8 h, is then 2-3 with 6mol/L salt acid for adjusting pH, then uses ether-acetic acid
The extraction of ethyl ester mixed liquor, until extract liquor is colourless, combining extraction liquid revolving freeze-drying obtains reference state polyphenol extract.
4. application according to claim 3, it is characterised in that: methanol-acetone mixed liquor is mass concentration 70-80% methanol
The ratio of solution and mass concentration 70-80% acetone soln 1:1-1:3 by volume are mixed to prepare.
5. application according to claim 3, it is characterised in that: ether-acetic acid ethyl ester mixed liquor is ether and ethyl acetate
The ratio of 1:1-1:3 is mixed to prepare by volume.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811170397.3A CN109172712A (en) | 2018-10-09 | 2018-10-09 | The purposes of palm berry extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811170397.3A CN109172712A (en) | 2018-10-09 | 2018-10-09 | The purposes of palm berry extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109172712A true CN109172712A (en) | 2019-01-11 |
Family
ID=64946944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811170397.3A Pending CN109172712A (en) | 2018-10-09 | 2018-10-09 | The purposes of palm berry extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172712A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088988A (en) * | 2008-04-02 | 2011-06-08 | 布兰代斯大学 | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| CN104542896A (en) * | 2014-12-22 | 2015-04-29 | 仲恺农业工程学院 | Film-based composite mangosteen polyphenol chilled meat preservative and preparation method thereof |
| CN105377283A (en) * | 2013-02-06 | 2016-03-02 | 布兰迪斯大学 | Treatment of dna damage and mitochondrial dysfunction using palm fruit juice |
-
2018
- 2018-10-09 CN CN201811170397.3A patent/CN109172712A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088988A (en) * | 2008-04-02 | 2011-06-08 | 布兰代斯大学 | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances |
| CN105377283A (en) * | 2013-02-06 | 2016-03-02 | 布兰迪斯大学 | Treatment of dna damage and mitochondrial dysfunction using palm fruit juice |
| CN104542896A (en) * | 2014-12-22 | 2015-04-29 | 仲恺农业工程学院 | Film-based composite mangosteen polyphenol chilled meat preservative and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| FELIX A. DADA ET AL.: ""Phenolic constituents and modulatory effects of Raffia palm leaf(Raphia hookeri)extract on carbohydrate hydrolyzing enzymes linked to type-2 diabetes"", 《JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE》 * |
| 念红丽等: ""成熟期对冬枣多酚含量及其抗氧化活性的影响"", 《食品工业科技》 * |
| 念红丽等: "高效液相色谱测定不同成熟期枣皮酚类物质 ", 《北京林业大学学报》 * |
| 李平等: "《中国五峰特色常见药用植物》", 30 September 2014, 湖北科学技术出版社 * |
| 陈天晴: ""膳食多酚抑制α-葡糖苷酶活性的构效关系研究"", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Composition and bioactivity of tea flower polysaccharides obtained by different methods | |
| Zhang et al. | α-Glucosidase inhibitors from Chinese yam (Dioscorea opposita Thunb.) | |
| Limpanit et al. | a-Glucosidase inhibitors from Dendrobium tortile | |
| Kasangana et al. | Further isolation and identification of anti-diabetic principles from root bark of Myrianthus arboreus P. Beauv.: The ethyl acetate fraction contains bioactive phenolic compounds that improve liver cell glucose homeostasis | |
| CN101570557B (en) | Compound in cyclocarya paliurus and application thereof in medicament field | |
| Jia et al. | Hypoglycemic activity of Codonopsis pilosula (Franch.) Nannf. in vitro and in vivo and its chemical composition identification by UPLC-Triple-TOF-MS/MS | |
| Liu et al. | Aporphine alkaloids identified from Xylopia aethiopica and their potential hypoglycemic and hypolipidemic activities | |
| CN103622972A (en) | Preparation method for compound 3 alpha-Akebonolic acid and application of compound to preparation of glycosidase inhibitor drug | |
| Huang et al. | Identification and Structure–Activity Relationship of Recovered Phenolics with Antioxidant and Antihyperglycemic Potential from Sugarcane Molasses Vinasse | |
| CN117204568A (en) | Rosa roxburghii dietary fiber-bonded polyphenol with remarkable hypoglycemic activity, and extraction method and application thereof | |
| CN103739652A (en) | New 23, 29-drop oleanolic acid compound, preparation method thereof and application in preparation of glucosidase inhibitor medicines | |
| CN109394932A (en) | The preparation method and application of palm fruit different conditions polyphenol extract | |
| CN103739653B (en) | A kind of 23-fall oleanane acid compound and preparation method thereof and the purposes in preparing glycosidase inhibitor | |
| Amare | Methanolic Extract of Myrsine africana Leaf Ameliorates Hyperglycemia and Dyslipidemia in Alloxan‐Induced Diabetic Albino Mice | |
| CN109172712A (en) | The purposes of palm berry extract | |
| CN113387997B (en) | Triterpene saponin compound with function of improving glycolipid metabolic disturbance and preparation and application thereof | |
| CN109350614A (en) | A kind of hypoglycemic purposes of piperlongumine alkaloid | |
| CN106565444B (en) | The extracting method and application of Chinese yam aerial part phenanthrene class compound | |
| CN109528862A (en) | A kind of Chinese medical extract, preparation method and application | |
| CN103613632B (en) | 29-falls volatile oil acid compounds and preparation method thereof and is preparing the application in glycosidase inhibitor | |
| CN101416970A (en) | Use of arjunolic acid in preparing glycosidase inhibitor | |
| JP6576445B2 (en) | Aromatic compounds of farnesyl and their applications | |
| CN103641882B (en) | Novel 2,3-dihydroxyl-30-noroleanolic acid as well as preparation method and application thereof in preparing glycosidase inhibitor medicament | |
| CN113004299A (en) | Xanthone compound in mangosteen bark for reducing postprandial blood sugar, and extraction method and application thereof | |
| Durgam et al. | Lupenone Isolated from Diospyros melanoxylon Bark Non-competitively Inhibits alpha-amylase Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |